<DOC>
	<DOCNO>NCT01046487</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose imatinib mesylate , give association fix dose cyclophosphamide ( 50 mg bid ) .</brief_summary>
	<brief_title>Imatinib Mesylate And Cyclophosphamide In Metronomic Administration : Dose Escalation Study Of Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Rare tumor metastatic disease locally advanced disease , inoperable , standard treatment At least 28 day since prior treatment Measurable disease least one measurable lesion Medullary insufficiency Cystitis , haemorrhagic cystitis Hepatic porphyria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>dermatofibrosarcoma</keyword>
	<keyword>cylindroma</keyword>
	<keyword>choroid melanoma</keyword>
	<keyword>gastrointestinal stroma tumor</keyword>
	<keyword>chordoma</keyword>
	<keyword>ocular melanoma</keyword>
	<keyword>conjunctival melanoma</keyword>
	<keyword>malignant melanoma anus</keyword>
	<keyword>gastric melanoma</keyword>
	<keyword>desmoid tumor</keyword>
</DOC>